Esker And Two High Growth Tech Stocks In France

Simply Wall St.
2024-09-24

With the recent Fed rate cuts and a cautious but optimistic outlook for monetary policy in Europe, the market sentiment has been buoyant, particularly benefiting smaller-cap stocks. In this context, high-growth tech stocks in France present intriguing opportunities for investors seeking dynamic growth potential. When evaluating such stocks, it's crucial to consider their innovation capabilities and adaptability to evolving market conditions.

Top 10 High Growth Tech Companies In France

Name Revenue Growth Earnings Growth Growth Rating
Icape Holding 14.08% 28.13% ★★★★★☆
Cogelec 11.33% 23.96% ★★★★★☆
Valneva 23.46% 25.74% ★★★★★☆
Munic 26.68% 149.10% ★★★★★☆
VusionGroup 28.35% 82.32% ★★★★★★
Oncodesign Société Anonyme 14.68% 101.18% ★★★★★☆
Adocia 70.20% 63.97% ★★★★★☆
beaconsmind 28.59% 133.36% ★★★★★★
Pherecydes Pharma Société anonyme 63.30% 78.85% ★★★★★☆
OSE Immunotherapeutics 30.02% 5.91% ★★★★★☆

Click here to see the full list of 45 stocks from our Euronext Paris High Growth Tech and AI Stocks screener.

Let's dive into some prime choices out of from the screener.

Esker

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Esker SA operates a cloud platform for finance and customer service professionals in France and internationally, with a market cap of €1.55 billion.

Operations: Esker SA generates revenue primarily from its Software & Programming segment, which brought in €202.22 million. The company offers cloud solutions aimed at finance and customer service sectors across various regions.

Amidst a dynamic M&A landscape, Esker SA has emerged as a focal point following the recent tender offer by General Atlantic and Bridgepoint Group valued at €1.58 billion, signaling robust investor confidence and underlining its strategic value in the software sector. Despite not outpacing the industry with a 10.3% earnings growth last year compared to the software industry's 10.8%, Esker is poised for significant advancements with an anticipated earnings growth of 27% annually over the next three years, surpassing the French market's forecast of 12.3%. This growth trajectory is supported by Esker’s commitment to R&D, crucial for sustaining innovation and competitive edge in tech-intensive markets.

  • Dive into the specifics of Esker here with our thorough health report.
  • Learn about Esker's historical performance.

ENXTPA:ALESK Revenue and Expenses Breakdown as at Sep 2024

Bolloré

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Bolloré SE operates in transportation and logistics, communications, and industry sectors across multiple continents including Europe, the Americas, Asia, Oceania, and Africa with a market cap of €17.12 billion.

Operations: The company's primary revenue streams are derived from its communications segment (€14.86 billion) and Bolloré Energy (€2.75 billion), with additional contributions from its industry sector (€353 million). The net profit margin for the latest period stands at 8.5%.

Bolloré SE has demonstrated a significant turnaround, with half-year sales soaring from €6.23 billion to €10.59 billion and net income escalating dramatically to €3.76 billion from just €114 million previously. This financial revitalization is underpinned by an aggressive R&D strategy, which not only fuels innovation but also aligns with its 8.3% revenue growth forecast, outpacing the French market's 5.7%. Moreover, Bolloré's earnings are projected to grow at an impressive rate of 32.7% annually, substantially exceeding the broader market prediction of 12.3%, reflecting its potential in high-growth tech sectors despite a modest return on equity forecast of 4.9%. The company's commitment to reinvesting in technology and expanding its market reach could position it favorably within France’s competitive tech landscape.

  • Click here and access our complete health analysis report to understand the dynamics of Bolloré.
  • Review our historical performance report to gain insights into Bolloré's's past performance.

ENXTPA:BOL Earnings and Revenue Growth as at Sep 2024

Genfit

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Genfit S.A. is a late-stage biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions for metabolic and liver-related diseases, with a market cap of €228.79 million.

Operations: Genfit S.A. specializes in the discovery and development of drug candidates and diagnostic solutions targeting metabolic and liver-related diseases. The company operates within the biopharmaceutical sector, focusing its efforts on late-stage clinical trials for innovative treatments.

Genfit S.A. has pivoted impressively, turning a net loss into a substantial €30.31 million profit as recent earnings illuminate. This transformation is anchored by a robust 17.8% revenue growth rate, surpassing the French tech market's average of 5.7%. Moreover, with R&D expenses tailored to foster innovation, Genfit's future seems promising as its earnings are projected to surge by 33.8% annually—outstripping the broader market forecast of 12.3%. This strategic focus on research not only fuels technological advancements but also positions Genfit advantageously in an increasingly competitive sector.

  • Get an in-depth perspective on Genfit's performance by reading our health report here.
  • Gain insights into Genfit's past trends and performance with our Past report.

ENXTPA:GNFT Earnings and Revenue Growth as at Sep 2024

Turning Ideas Into Actions

  • Delve into our full catalog of 45 Euronext Paris High Growth Tech and AI Stocks here.
  • Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
  • Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Ready For A Different Approach?

  • Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
  • Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
  • Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ENXTPA:ALESK ENXTPA:BOL and ENXTPA:GNFT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10